Supplementary Table 2: Co-existing *PIK3CA* and *KRAS* mutations.

Type of cancer	Patients tested for *PIK3CA* and *KRAS*	*PIK3CA* and *KRAS* mutations (% in subgroup)	*PIK3CA* mutation and wild-type *KRAS* (% in subgroup)	*PIK3CA* wild-type and *KRAS* mutation (% in subgroup)	*PIK3CA* and *KRAS* wild-type (% in subgroup)	P value
All tumor types	717	31 (4)	55 (8)	106 (15)	525 (73)	<0.001
Colorectal cancer	176	22 (12.5)	9 (5)	63 (36)	82 (46.5)	0.006[a]
Ovarian cancer	85	4 (5)	6 (7)	4 (5)	71 (83)	0.006[a]
Endometrial cancer	34	3 (9)	7 (20)	3 (9)	21 (62)	0.33
Pancreatic cancer	21	1 (5)	0 (0)	12 (57)	8 (38)	NA[b]
Appendiceal cancer	5	1 (20)	0 (0)	3 (60)	1 (20)	NA[b]

[a] *PIK3CA* mutations were associated with *KRAS* mutations in colorectal and ovarian cancers.
[b] Low numbers preclude statistical analysis